Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAVEN in Newly Diagnosed KMT2A-Rearranged AML
NCT07605949Phase 2Not yet recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Oct 2026
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of revumenib in acute myeloid leukemia (AML), sponsored by UNC Lineberger Comprehensive Cancer Center. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
revumenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07605949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07605949.